Fig. 4
- ID
- ZDB-FIG-240305-8
- Publication
- Zorman et al., 2023 - The overview of development of novel bacterial topoisomerase inhibitors effective against multidrug-resistant bacteria in an academic environment: from early hits to in vivo active antibacterials
- Other Figures
- All Figure Page
- Back to All Figure Page
|
Gradual structural and physicochemical optimizations of different NBTIs showing diminished hERG inhibition, while maintaining excellent antibacterial properties. Overall, more than a 100-fold hERG improvement was achieved after differentially fluorinating the p-halogenated phenyl RHS moieties (Kokot et al., 2021), and by substituting the aminopiperidine linker with more polar linker variant that does not contain a tertiary amine (Kokot et al., 2022). Furthermore, compound 6, exhibits no cardiotoxicity in vivo zebrafish model, and a favorable in vivo efficacy in a neutropenic murine thigh infection model of MRSA (Kokot et al., 2023). |